enGene Therapeutics (ENGN) Free Cash Flow (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Free Cash Flow of -$30.6 million for Q2 2026, down 33.09% year-over-year from -$45.7 million in Q2 2025, and down 5.32% quarter-over-quarter from -$29.1 million in Q1 2026.
enGene Therapeutics (ENGN) Free Cash Flow (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Free Cash Flow for 4 consecutive years, with -$30.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Free Cash Flow fell 33.09% year-over-year to -$30.6 million; the TTM figure through Apr 2026 stood at -$110.2 million (down 45.09% YoY), while the FY2025 annual figure was -$99.6 million, down 102.36% from the prior year.
- Free Cash Flow fell to -$30.6 million in Q2 2026 per ENGN's latest filing, from -$29.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$4.5 million in Q2 2023 and bottomed at -$30.6 million in Q2 2026.
- Historically, Free Cash Flow has averaged -$16.7 million across 4 years, with a median of -$17.1 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow advanced 3.67% — and 2025, when it sank 266.67%.
- enGene Therapeutics' Free Cash Flow stood at -$6.9 million in 2023, then plunged by 186.46% to -$19.8 million in 2024, then fell by 22.42% to -$24.2 million in 2025, then decreased by 26.2% to -$30.6 million in 2026.
- Business Quant data shows ENGN's Free Cash Flow at -$30.6 million in Q2 2026, -$29.1 million in Q1 2026, and -$24.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -30.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -30.60 Mn |
| Apr 30, 2026 | -30.60 Mn |
| Jan 31, 2026 | -29.05 Mn |
| Jan 31, 2026 | -29.05 Mn |
| Oct 31, 2025 | -24.25 Mn |
| Oct 31, 2025 | -24.25 Mn |
| Jul 31, 2025 | -26.34 Mn |
| Jul 31, 2025 | -26.34 Mn |
| Apr 30, 2025 | -22.99 Mn |
| Apr 30, 2025 | -22.99 Mn |
| Jan 31, 2025 | -26.00 Mn |
| Jan 31, 2025 | -26.00 Mn |
| Oct 31, 2024 | -19.81 Mn |
| Oct 31, 2024 | -19.81 Mn |
| Jul 31, 2024 | -7.18 Mn |
| Jul 31, 2024 | -7.18 Mn |
| Apr 30, 2024 | -14.34 Mn |
| Apr 30, 2024 | -14.34 Mn |
| Jan 31, 2024 | -7.88 Mn |
| Jan 31, 2024 | -7.88 Mn |